To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A

Phase 1 to evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A. Which is designed as two cohort, single-sequence, paralle, open label, multiple oral dosing.

Inclusion Criteria:

• Over 19 ages healty men
• Over 50.0kg, 18.0kg/m2 ≤ BMI ≤30.0kg/m2
• Men who dont have congenital disease and other cronic disease need to be cared etc.

Exclusion Criteria:

• Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN)
• Men who have drunken or eatten something including carffeine within 24 hours before etc.